Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UB 311

Drug Profile

UB 311

Alternative Names: Alzheimer's disease vaccine - United Biomedical; Amyloid-beta-1-14-vaccine; UB311; UBITh AD immunotherapeutic vaccine

Latest Information Update: 05 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator United Biomedical
  • Class Alzheimer vaccines; Antidementias; Peptide vaccines; Synthetic vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 30 Jan 2024 Vaxxinity and Center for Translational Research in Neurodegenerative Disease (CTRND) enters into a research collaboration agreement to develop immunotherapies to prevent and mitigate neurodegenerative diseases
  • 10 Aug 2023 Efficacy data from a phase IIa trial in Alzheimer's disease released by Vaxxinity
  • 31 Dec 2022 UB 311 is available for licensing as of 31 May 2022. https://www.sec.gov/ix?doc=/Archives/edgar/data/1851657/000156276223000132/vaxxq410k.htm
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top